Discovery and characterization of potent and selective 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acids as S1P1 agonists.
Bioorg Med Chem Lett
; 21(19): 6013-8, 2011 Oct 01.
Article
em En
| MEDLINE
| ID: mdl-21852130
ABSTRACT
S1P(1) receptor driven lymphopenia has proven utility in the treatment of an array of autoimmune disease states. As a part of our efforts to develop potent and selective S1P(1) receptor agonists, we have identified a novel chemical series of 4-oxo-4-(5-(5-phenyl-1,2,4-oxadiazol-3-yl)indolin-1-yl)butanoic acid S1P(1) receptor agonists.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Oxidiazóis
/
Doenças Autoimunes
/
Butiratos
/
Linfócitos
/
Proteínas de Ligação a RNA
/
Imunossupressores
/
Indóis
/
Proteínas do Tecido Nervoso
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article